» Articles » PMID: 15593087

Akt Phosphorylation is a Risk Factor for Early Disease Recurrence and Poor Prognosis in Hepatocellular Carcinoma

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2004 Dec 14
PMID 15593087
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients with hepatocellular carcinoma (HCC) who showed early massive disease recurrence due to hematogenous intrahepatic metastasis after curative resection had a poor prognosis. The authors previously reported that Akt phosphorylation was correlated with hematogenous intrahepatic metastasis, using HCC cell lines.

Methods: The authors analyzed clinicopathologic features and the status of selected biologic markers, including phosphorylated Akt, to identify risk factors for early disease recurrence and poor prognosis in HCC. In the current series, 49 postoperative patients developed intrahepatic disease recurrence within 6 months (Group 1) and 86 patients remained disease recurrence free > 3 years after resection (Group 2). Group 1 was further divided into 2 subgroups: 19 patients who died of disease recurrence within a year after resection (Group 1A) and 27 patients who survived > 1 year (Group 1B).

Results: Using univariate analysis, the risk factors for early disease recurrence were tumor size, macroscopic classification, tumor differentiation, microscopic capsule infiltration, microscopic portal vein (MPV) invasion, microscopic intrahepatic metastasis (MIM), and positive immunostaining for phosphorylated Akt, Ki-67, and p53 (P < 0.05). The risk factors for poor prognosis were the number of intrahepatic metastases, tumor differentiation, and positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05). Multivariate analysis revealed that the risk factors for early disease recurrence were MPV invasion, MIM, and positive immunostaining for phosphorylated Akt, and that the risk factors for poor prognosis were positive immunostaining for phosphorylated Akt and Ki-67 (P < 0.05).

Conclusions: The current clinical study showed the critical involvement of Akt phosphorylation in the aggressiveness of HCC. The potential benefits of surgery should be assessed carefully in patients with any of these risk factors.

Citing Articles

Overlap of Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Matched Tissues for Proteomics and Phosphoproteomics.

Humphries E, Hains P, Robinson P ACS Omega. 2025; 10(7):6891-6900.

PMID: 40028131 PMC: 11865994. DOI: 10.1021/acsomega.4c09289.


Knockdown of CENPF induces cell cycle arrest and inhibits epithelial‑mesenchymal transition progression in glioma.

Li J, Liu L, Zong G, Yang Z, Zhang D, Zhao B Oncol Lett. 2024; 29(1):61.

PMID: 39611064 PMC: 11602827. DOI: 10.3892/ol.2024.14807.


Combination of Gene Therapy and Chemotherapy in a New Targeted Hybrid Nanosystem to Hepatocellular Carcinoma.

Farinha D, Sarmento-Ribeiro A, Faneca H Int J Nanomedicine. 2024; 19:12505-12527.

PMID: 39606562 PMC: 11598603. DOI: 10.2147/IJN.S474665.


DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway.

Zhang J, Shi Y, Ding K, Yu W, He J, Sun B J Exp Clin Cancer Res. 2024; 43(1):136.

PMID: 38711082 PMC: 11071249. DOI: 10.1186/s13046-024-03055-2.


Predicting Ki-67 expression in hepatocellular carcinoma: nomogram based on clinical factors and contrast-enhanced ultrasound radiomics signatures.

Zhang D, Zhang X, Lu W, Liao J, Zhang C, Tang Q Abdom Radiol (NY). 2024; 49(5):1419-1431.

PMID: 38461433 DOI: 10.1007/s00261-024-04191-1.